Previous 10 | Next 10 |
Guardant Health ([[GH]] -1.0%) is trading marginally lower today as a recent SEC filing submitted by the company indicates that SoftBank Vision Fund a subsidiary of famed Japanese conglomerate Softbank Group has cut its investment in company shares.SoftBank Vision Fund which previously o...
A new study published in Clinical Cancer Research demonstrates that Guardant Health's (GH) Guardant Reveal, the first blood-only liquid biopsy to identify minimal residual disease ((MRD)), identifies patients most likely with cancer recurrence, without the need for tumor tissue...
For patients with early-stage colorectal cancer (CRC), the presence of circulating tumor DNA (ctDNA) or minimal residual disease (MRD) after curative intent treatment is becoming an important prognostic biomarker for cancer recurrence, and can also be used to evaluate the potential need...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming BofA Securities 2021 Healthcare Conference. Guardant Health’s management is scheduled to participate in a fireside chat on Wednesday, Ma...
Guardant Health (GH) collaborates with Daiichi Sankyo (DSKYF) to pursue regulatory approval and commercialization of the Guardant360 CDx blood test as a companion diagnostic for Enhertu being studied in the treatment of advanced metastatic non-small cell lung cancer ((NSCLC)). The Guarda...
Guardant Health, Inc. (Nasdaq: GH) today announced a strategic collaboration with Daiichi Sankyo, Inc. (Daiichi Sankyo) to pursue regulatory approval and commercialization of the Guardant360 ® CDx blood test as a companion diagnostic for Enhertu ® (fam-trastuzumab deru...
You're already used to having your blood drawn at the doctor's office. It's simple. A clinician jabs your vein with a hypodermic needle while you squeamishly look the other way, extracts a sample, and in less time than it takes to find a parking spot at the doctor's office, you're done. ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2021 after market close on Thursday, May 6, 2021. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m....
Insider buying decreased significantly last week. Notable Insider Buys: HighPeak Energy, Inc., William Penn Bancorporation, Bioventus Inc., Athenex, Inc., Sensei Biotherapeutics, Inc. Notable Insider Sells: Facebook, Inc., Ulta Beauty, Inc., Guardant Health, Inc., Applied Material...
Phase 2 trial of Amgen’s investigational KRAS G12C inhibitor, sotorasib, demonstrated comparable efficacy between patients identified as KRAS G12C positive using Guardant360 CDx liquid biopsy or tissue biopsy Guardant Health, Inc. (Nasdaq: GH), along with lead...
News, Short Squeeze, Breakout and More Instantly...
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...